Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 4,151 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Small Cell Lung Carcinoma Clear all
Completed Phase 1Phase 2 Interventional

Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer

NCT00073723
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ABI-007
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Trial of Poor Performance Status Patients (ToPPS)

NCT00892710
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pemetrexed, Bevacizumab, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
27
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer

NCT00297089
View directory record Official record
Conditions
Lung Cancer, NSCLC, Non-Small-Cell Lung Cancer
Interventions
ABT-751, pemetrexed, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
27
States / cities
Fayetteville, Arkansas • Hot Springs, Arkansas • Greenbrae, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

NCT00147537
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
CP-751,871, paclitaxel, carboplatin, erlotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
26
States / cities
Tucson, Arizona • Greenbrae, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Oct 6, 2026, 1:09 PM EDT
Active, not recruiting Phase 1 Interventional

Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer

NCT04073745
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Positive Surgical Margin, Resected Mass, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Other · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases

NCT00372775
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Norwalk, Connecticut • Cocoa Beach, Florida • Merritt Island, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2011 · Synced Oct 6, 2026, 1:09 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

NCT06732401
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Echocardiography Test
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
192
States / cities
Jonesboro, Arkansas • Beverly Hills, California • Los Angeles, California + 163 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed No phase listed Observational

Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers

NCT00684801
View directory record Official record
Conditions
Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
questionnaire administration, quality-of-life assessment
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 6, 2026, 1:09 PM EDT
Completed No phase listed Observational

Aerosolized Liposomal Camptothecin in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung

NCT00277082
View directory record Official record
Conditions
Corpus Uteri, Lung Cancer
Interventions
9-NC in aerosol reservoir
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2 Interventional

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

NCT05429320
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Nsclc, NSCLC Stage IV, Minimal Residual Disease, Non Small Cell Lung Cancer Metastatic
Interventions
Local ablative therapy, Blood collection to assess for ctDNA
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2 Interventional

TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00036920
View directory record Official record
Conditions
Lung Cancer
Interventions
canfosfamide hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer

NCT00002823
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, vinblastine sulfate, vindesine, vinorelbine tartrate, radiation therapy
Drug · Radiation
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Other
Eligibility
18 Years to 75 Years
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
2
States / cities
Atlantis, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Oct 6, 2026, 1:09 PM EDT
Not listed Phase 2 Interventional

An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation

NCT01260480
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms
Interventions
[18F]-ML-10 in conjunction with PET imaging
Other
Lead sponsor
Aposense Ltd.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
4
States / cities
Boston, Massachusetts • Teaneck, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2010 · Synced Oct 6, 2026, 1:09 PM EDT
Withdrawn Phase 1Phase 2 Interventional

CISH Inactivated TILs in the Treatment of NSCLC

NCT05566223
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
Interventions
Fludarabine, Cyclophosphamide, CISH Inactivated TIL, Aldesleukin, Pembrolizumab
Drug · Biological
Lead sponsor
Intima Bioscience, Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Duarte, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2 Interventional

Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00293280
View directory record Official record
Conditions
Lung Cancer
Interventions
lomustine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Metastatic Cancer

NCT00004604
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
CEA RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 6, 2026, 1:09 PM EDT
Terminated Phase 1 Interventional

A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

NCT05983133
View directory record Official record
Conditions
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
Interventions
PF-08046052
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
22
States / cities
Los Angeles, California • Santa Monica, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Terminated Phase 3 Interventional

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00551733
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, paclitaxel poliglumex
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
41
States / cities
Scottsdale, Arizona • Burbank, California • Escondido, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

NCT00019084
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
aldesleukin, mutant p53 peptide pulsed dendritic cell vaccine, ras peptide cancer vaccine, sargramostim, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

NCT00019825
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
Interventions
decitabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 3 Interventional Results available

Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer

NCT00363415
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
pemetrexed, etoposide, carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
54
States / cities
Huntsville, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2009 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

NCT06669117
View directory record Official record
Conditions
Solid Tumor, MET Alteration
Interventions
VERT-002
Drug
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Canton, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting Not applicable Interventional

Patient-centered, Optimal Integration of Survivorship and Palliative Care

NCT04900935
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer, Targeted Therapy, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, ALK-positive Non-small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer, Palliative Care, Survivorship
Interventions
POISE
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 3 Interventional

Study to Evaluate SID 530 Compared to Taxotere

NCT00931008
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
SID530, Taxotere
Drug
Lead sponsor
SK Chemicals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Miami, Florida • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 6, 2026, 1:09 PM EDT